Pictura Bio US, Inc. — SEC Form D Filing
Pictura Bio US, Inc. filed an SEC Form D on September 25, 2026, reporting $9.13M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 25, 2026
- Amount reported
- $9.13M
- Round stage
- Seed
- Industry
- Biotechnology
- Website
- https://pictura.bio/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Current point-of-care infectious disease diagnostics are often too slow, require multiple pathogen-specific reagents, and contribute to inappropriate antibiotic prescriptions due to delayed or inaccurate results.
Solution
Pictura Bio is developing VISTA, a pathogen detection platform that uses computer vision, a single universal reagent (PIC-ID Capture), and digital image analysis (PIC-ID Identify) to instantly detect and differentiate pathogens at the point of care.
Why now
Advances in computer vision and AI, coupled with the ongoing need for rapid, accessible, and accurate infectious disease diagnostics (highlighted by events like pandemics and antibiotic resistance concerns), make this technology timely.
Verdict
Investors backed this round as a bet on a paradigm shift in rapid diagnostics driven by advances in computer vision, not merely another incremental improvement in existing point-of-care testing. They implicitly bet that Pictura Bio could translate a compelling technical concept into a regulated, scalable medical device capable of displacing established diagnostic workflows. The upside was limited by the inherent regulatory and clinical validation hurdles common in biotech, requiring significant additional capital and time before commercial traction could be reliably assessed.
Source: SEC EDGAR Form D filing